Myriad settles BRCA litigation following Federal Circuit ruling

January 29 2015

Myriad Genetics has settled litigation with three of the laboratories it accused of infringing patents on two genes associated with breast and ovarian cancer, following a Federal Circuit ruling last month confirming some of its claims were patent ineligible

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

more from across site and SHARED ros bottom lb

More from across our site

Patents

‘You will never get bored’: Groombridge Wu founder on building a firm

Nick Groombridge shares how an accidental turn into patent law informed his approach to building a practice based on flexibility and balancing client and practitioner needs

Sanjana Mishra, December 17 2025

Patents

‘Roll the dice more’: the business of innovation

Clarivate’s Ed White discusses the joy of measuring innovation and why patent attorneys are a special breed

December 17 2025

Patents

Blick auf die Business Bay in Dubai mit den modernen Wolkenkratzern bei Sonnenaufgang

Exclusive: UK and Netherlands join AIPPI Dubai criticism

National groups for the UK and the Netherlands have flagged concerns with the choice of venue, following a formal complaint from Australia’s national group

Max Walters, December 16 2025

50 most influential people in IP